An interventional study of Wearing smart insoles in Stroke, Incomplete Spinal Cord Injury and Traumatic Brain Injury, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Stroke by University Hospital, Ghent — 9 open to participants now, 9 under way, none of them phase 3. Stroke · University Hospital, Ghent.
Among the 18 studies in Stroke by University Hospital, Ghent, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, and was the 16th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →9 of the 18 studies in Stroke by University Hospital, Ghent are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+ · Healthy volunteers
University Hospital, Ghent · Sites in Belgium
Ages 18+
University Hospital, Ghent · Sites in Belgium
Ages 18+
University Hospital, Ghent · Sites in Belgium
Ages 18–70 · Healthy volunteers
University Hospital, Ghent · Sites in Belgium
Ages 18–70
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 30 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 30 across the 13 interventional studies, 260 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
4 of the studies in Stroke by University Hospital, Ghent that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06442579University Hospital, GhentThe Influence of Cortical Lateralization on Selective Motor Control of the Arm Swing During Independent Walking After Stroke. | 2026-12-30 |
| NCT07059351University Hospital, GhentOral Status as Predictors of Stroke-Associated Pneumonia and Swallowing Recovery in Patients With Post-Stroke Dysphagia | 2027-07-01 |
| NCT06847217University Hospital, GhentEffect of Applying Oral Hygiene Care on Swallowing in Stroke Patients With Oropharyngeal Dysphagia | 2027-10-01 |
| NCT07387328University Hospital, GhentValidation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Stroke by University Hospital, Ghent, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ceriter Stride-One soles have been available on the market for several years. One of the features of these soles is that they can measure gait parameters while patients walk around in a functional environment. This can provide a more realistic picture of gait patterns compared to measurements taken in a laboratory setting.
At UZ Ghent, we use an advanced gait lab to measure gait parameters before and after a training period on this system, the GRAIL system. We measure similar parameters to the Ceriter Stride-One soles (support phase, swing phase, pressure on the left leg and on the right leg). In this study, we would apply these insoles to patients who are tested on the GRAIL system, according to standard care, during the test in order to compare the parameters measured by the insoles and the parameters measured by the GRAIL system. This information will give us more insight into the accuracy of the data measured with these soles so that we can apply them in future studies conducted not in the gait lab but in functional environments.
Patients who are eligible for GRAIL therapy and are therefore routinely tested are patients who are admitted or undergoing outpatient rehabilitation at the rehabilitation centre of UZ Ghent after a brain injury, stroke, spinal cord injury or amputation. Given the subject of the research and the difficulty of fitting a sole into the shoe of a prosthetic leg, only people with brain and spinal cord injuries are asked to participate in the study.
Participants must be able to step onto the GRAIL treadmill with the help of one therapist and must be able to walk for at least six minutes. Participants have to weigh less than 120 kg (treadmill safety system restriction).
As standard in our setting, participants train for 5 weeks, twice a week for 30 minutes on the GRAIL treadmill. Before and after their training period, they walk on the GRAIL for about 2 minutes and we measure a number of gait parameters: speed, step width, step length, duration of the support phase and swing phase, and how much they support on their left and right legs.
Some of these parameters can also be measured by the Ceriter Stride One sole. The aim is to investigate how comparable these data are. If these data are sufficiently comparable, the soles can be used to measure the ratio of the support and swing phases during walking in everyday tasks or in environments other than a laboratory setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is the group wearing smart insoles, it is the only group
Device: Wearing smart insoles
Participants will wear Ceriter Stride One insoles during walking on an instrumented treadmill. Parameters (like stance phase duration and swing phase duration) measured by the insoles will be compared to the same parameters measured by the instrumented treadmill with accompanying 3D motion capture system.
Swing phase as a percentage of the duration of one stride
For each leg the duration of the swing phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between toe-off and the following heel contact of the same leg. Using the ceriter stride one insole this will be calculated by determining the toe-off and following heel contact based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.
Time frame: Single point of assessment at inclusion
Stance phase as a percentage of the duration of one stride
For each leg the duration of the stance phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between heel contact and the following toe-off of the same leg. Using the ceriter stride one insole this will be calculated by determining the heel contact and following toe-off based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.
Time frame: Single point of assessment at inclusion
Stance phase as a percentage of the duration of one stride after 5 weeks
For each leg the duration of the stance phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between heel contact and the following toe-off of the same leg. Using the ceriter stride one insole this will be calculated by determining the heel contact and following toe-off based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.
Time frame: Single point of assessment at 5 weeks after inclusion
Swing phase as a percentage of the duration of one stride after 5 weeks
For each leg the duration of the swing phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between toe-off and the following heel contact of the same leg. Using the ceriter stride one insole this will be calculated by determining the toe-off and following heel contact based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.
Time frame: Single point of assessment at 5 weeks after inclusion
Ratio of stance phase duration
The ratio of the stance phase duration of the paretic leg will be calculated compared to the non-paretic leg. Or if both legs are involved, the ratio of the most impaired leg on the least impaired leg. This will determine the asymmetry in stance phase duration during walking.
Time frame: Single point of assessment at inclusion
Ratio of stance phase duration after 5 weeks
The ratio of the stance phase duration of the paretic leg will be calculated compared to the non-paretic leg. Or if both legs are involved, the ratio of the most impaired leg on the least impaired leg. This will determine the asymmetry in stance phase duration during walking.
Time frame: Single point of assessment at 5 weeks after inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 10 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.